Search for: "Grant v. Bristol-Myers Squibb" Results 101 - 120 of 158
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 May 2012, 4:23 am by Max Kennerly, Esq.
Bristol-Myers Squibb Co., 2011 WL 2784101, at *3 (D.N.J. 2011), the Court did not hold that the warning label was enough to give notice. [read post]
20 May 2012, 1:11 pm
  The number 50 million:  The number of people in the US since 1997, that have taken Bristol-Myers Squibb's blood-thinning drug Plavix. [read post]
19 Mar 2012, 4:16 am
Judge Birss QC assures us that his decision in Merck Sharp Dohme Corp & Anor v Teva Pharma BV & Anor [2012] EWHC 627 (Pat), relating to an application by Bristol-Myers Squibb for an interim injunction pending trial, raises no issue of principle, but he does provide an enlightening discussion of how to address some issues of fact that are common in an application for a quia timet injunction, including a review of the European case law. [read post]
30 Aug 2011, 2:00 am by Stefanie Levine
US 6,475,521entitled BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD and owned by Bristol-Myers Squibb Co. [read post]
30 Aug 2011, 2:00 am by Stefanie Levine
US 6,475,521entitled BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD and owned by Bristol-Myers Squibb Co. [read post]
25 Aug 2011, 7:01 am by Bexis
 Id. at 17-18.Finally, plaintiff was granted leave to amend (negligence only) in Salvio, slip op. at 18-19. [read post]
26 Mar 2011, 5:00 pm
Bristol-Myers Squibb Co. v. [read post]
24 Mar 2011, 1:12 pm by FDABlog HPM
Bristol-Myers Squibb, Inc., the employees claim that BMS paid kickbacks to physicians and pharmacists to increase prescriptions and dispensing of the company’s drugs. [read post]
18 Feb 2011, 11:47 am by Sheppard Mullin
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
16 Feb 2011, 12:04 am by war
It looks like they would also do away with all the problems of the “threshold” requirement introduced by Phillips v Mirabella (the nature of the problem is laid out at paragraphs 19 to 27 of Bristol-Myers Squibb v Faulding). [read post]
10 Dec 2010, 3:06 am by Andrew Lavoott Bluestone
Inc., 2000 US Dist LEXIS 21316, *12-13 [2000]; Grant v Bristol-Myers Squibb, 97 F Supp 2d 986, 992 [2000]). [read post]
24 Nov 2010, 12:37 am by Kelly
Use of pipeline system (IP tango) EU: Notes from EU Parliament meeting on innovation+access for medical technologies (KEI) Netherlands: District Court of The Hague declares Dutch part of Bayer’s European patent covering anti-TNF alpha human monoclonal antibodies invalid (Kluwer Patent Blog) Southeast Asia: Generic drug market picks up steam in Southeast Asia, finds Front & Sullivan (GenericsWeb) Spain: Commercial Court No 5 of Barcelona: obtaining price for generic medicament an act of… [read post]
17 Nov 2010, 1:48 am by Kelly
(Patents Post Grant Blog) US: University inventions, Stanford vs Roche (IPEG) US: What ultimately matters in deciding the ‘gene patenting’ issue? [read post]
9 Nov 2010, 3:09 pm
The patent also was granted a pediatric exclusivity period and will expire in February 2014. [read post]